DarioHealth Corp.
NASDAQ:DRIOMedical - Diagnostics & Research
-$0.12 today
- Market cap
- $50.27M
- Beta
- 1.08
- P/E (TTM)
- 5.5
- EPS (TTM)
- $1.26
Volume 0.01M
Average 0.01M
DRIO Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
DarioHealth Corp.NASDAQ: DRIO
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization declines year over year
Q1 FY2026 depreciation & amortization of $463K fell 63.1% year over year, ahead of the -72.3% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 104.0% from the prior quarter. Over 3 fiscal years it compounded at -15.6% a year.
Context
- Depreciation & amortization amounted to 12.7% of revenue in FY2025, down 14.8 pp from a year earlier.
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -63.1% holds above the trailing-twelve-month pace of -72.3%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 2.83M USD
- Year-over-year change
- -61.9%
- 4-year CAGR
- -10.7%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.83M | -61.9% |
| FY2024 | 2024-12-31 | 7.43M | +49.0% |
| FY2023 | 2023-12-31 | 4.99M | +5.7% |
| FY2022 | 2022-12-31 | 4.72M | +5.8% |
| FY2021 | 2021-12-31 | 4.46M | — |
Depreciation & Amortization vs competitors
How DRIO compares with its peers on the latest reported figures
- DRIO's LTM Mar 2026 depreciation & amortization of $2.04M is the 9th largest of the 11 companies compared; the peer median is $18.75M.
- Its year-over-year change of -72.3% is the 9th highest of 10, against a peer median of -8.6%.
- Depreciation & amortization amounts to 9.6% of revenue for DRIO, versus a peer median of 6.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $136.43M | +43.1% | +37.4% | 16.5% | |
| LTM Mar 2026 | $51.8M | -13.5% | +0.6% | 6.2% | |
| LTM Mar 2026 | $39.5M | -9.6% | -6.6% | 5.5% | |
| LTM Mar 2026 | $24.2M | +0.1% | -9.6% | 7.6% | |
| LTM Mar 2026 | $19.81M | -8.6% | +10.8% | 2.1% | |
| LTM Mar 2026 | $17.69M | -95.7% | +181.5% | 11.1% | |
| LTM Mar 2026 | $15.52M | -3.0% | +6.5% | 17.7% | |
| LTM Mar 2026 | $11.4M | -12.6% | -3.6% | 620.8% | |
| LTM Mar 2026 | $2.04M | -72.3% | -15.6% | 9.6% | |
| LTM Mar 2026 | $997K | +3223.3% | — | 2.0% | |
NNNNAnbio Biotechnology Class A Ordinary Shares | FY2025 | $0 | — | — | 0.0% |
| Peer median (excluding DRIO) | $18.75M | -8.6% | +3.6% | 6.9% | |
Competitors are the stored peer set for DRIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (76.76M) | (62.19M) | (59.43M) | (42.75M) | (41.71M) |
| Depreciation & Amortization | 4.46M | 4.72M | 4.99M | 7.43M | 2.83M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 24.97M | 16.98M | 19.7M | 15.8M | 9.37M |
| Change in Working Capital | (2.57M) | (10.9M) | 4.07M | (2.47M) | 2.21M |
| Accounts Receivables | (367K) | (5.11M) | 2.84M | 1.6M | 2.64M |
| Inventory | (2.23M) | (1.73M) | 2.89M | 308K | 437K |
| Accounts Payables | 1.08M | (2.79M) | (1.19M) | (496K) | (122K) |
| Other Working Capital | (1.06M) | (1.28M) | (464K) | (3.88M) | (752K) |
| Other Non-Cash Items | (503K) | 3.56M | 288K | (16.57M) | 1.37M |
| Operating Cash Flow | (50.41M) | (47.85M) | (30.38M) | (38.56M) | (25.94M) |
| Capital Expenditures | (261K) | (573K) | (584K) | (138K) | (142K) |
| Acquisitions (Net) | (7.47M) | 0 | 0 | (8.8M) | 0 |
| Purchases of Investments | 0 | 0 | (5M) | 0 | (4.2M) |
| Sales of Investments | 0 | 0 | 5.03M | 0 | 0 |
| Other Investing Activities | (400K) | (131K) | 0 | 0 | 0 |
| Investing Cash Flow | (8.13M) | (573K) | (547K) | (8.93M) | (4.34M) |
| Debt Repayment | 0 | 23.79M | 1.77M | 0 | 185K |
| Common Stock Issued | 64.88M | 38.29M | 1.61M | 0 | 24.13M |
| Common Stock Repurchased | 0 | (134K) | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 889K | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 65.77M | 61.94M | 18.25M | 38.53M | 24.31M |
| Effect of Forex Changes | 0 | 0 | 0 | (68K) | 9K |
| Net Change in Cash | 7.22M | 13.52M | (12.67M) | (9.03M) | (5.96M) |
| Free Cash Flow | (50.67M) | (48.42M) | (30.96M) | (38.7M) | (26.08M) |
DarioHealth Corp.
NASDAQ:DRIO
Intrinsic Alpha fair value
Locked
Current Price
$5.13
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.